RELIEF THERAPEUTICS Holding AG Revenue and Competitors

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) "Relief" is a biopharmaceutical company whose objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need. We focus on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use (well-established safety and tolerability) and either initial human activity with efficacy data (proof-of-concept) or a strong scientific rationale. Our most advanced programs involve our lead compound RLF-100â„¢, a synthetic human vasoactive intestinal peptide (VIP) with multifaceted mode of action, in respiratory indications: COVID-19 induced lung injury with major near-term milestones and pulmonary sarcoidosis, two diseases for which no transformational therapy exists. Clinical development of RLF-100â„¢ for other indications in both acute and chronic lung diseases are in planning stages. Since July 2020, severe COVID-19 patients have been treated with intravenous RLF-100â„¢ under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Program authorization for the treatment of respiratory failure in COVID-19 with early promising results. The program has been recently submitted for U.S. Emergency Use Authorization. The second Phase 2b/3 trial is slated to begin enrolling patients with moderate respiratory symptoms of COVID-19 infection in the coming weeks and is assessing an inhaled formulation of RLF-100â„¢, which is to be administered via nebulization. RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.